免疫组化重现外周T细胞淋巴瘤-NOS的分子亚型分类
研究基于基因表达谱已定义的外周T细胞淋巴瘤-非特指型(PTCL-NOS)两个分子亚型(PTCL-GATA3和PTCL-TBX21),开发免疫组化算法(GATA3、TBX21及其靶蛋白CCR4、CXCR3)在石蜡组织中识别亚型。
要点
- 免疫组化算法可高敏感性(85%)重现PTCL-NOS的GATA3/TBX21分子亚型。
核心结论
- 免疫组化算法可在石蜡组织中识别PTCL-NOS的PTCL-GATA3和PTCL-TBX21亚型,与基因表达谱分类高度一致。
- 两亚型总生存差异显著,PTCL-GATA3为独立不良预后因素。
研究设计与样本
- 研究基于既往基因表达谱定义的两个分子亚型,开发免疫组化算法使用GATA3、TBX21、CCR4和CXCR3抗体。
- 训练队列为49例有对应基因表达谱数据的PTCL-NOS病例,验证队列为124例PTCL-NOS病例。
关键数值与推荐
- 免疫组化算法使用GATA3、TBX21及其靶蛋白CCR4和CXCR3抗体。
- 训练队列中与基因表达谱匹配敏感性为85%。
临床怎么用
- 免疫组化算法有助于在临床实践中识别PTCL-NOS的两种亚型,辅助患者临床管理和临床试验风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of mature T-cell malignancies; approximately one-third of cases are designated as PTCL-not otherwise specified (PTCL-NOS). Using gene-expression profiling (GEP), we have previously defined 2 major molecular subtypes of PTCL-NOS, PTCL-GATA3 and PTCL-TBX21, which have distinct biological differences in oncogenic pathways and prognosis. In the current study, we generated an immunohistochemistry (IHC) algorithm to identify the 2 subtypes in paraffin tissue using antibodies to key transcriptional factors (GATA3 and TBX21) and their target proteins (CCR4 and CXCR3). In a training cohort of 49 cases of PTCL-NOS with corresponding GEP data, the 2 subtypes identified by the IHC algorithm matched the GEP results with high sensitivity (85%) and showed a significant difference in overall survival (OS) (P = .03). The IHC algorithm classification showed high interobserver reproducibility among pathologists and was validated in a second PTCL-NOS cohort (n = 124), where a significant difference in OS between the PTCL-GATA3 and PTCL-TBX21 subtypes was confirmed (P = .003). In multivariate analysis, a high International Prognostic Index score (3-5) and the PTCL-GATA3 subtype identified by IHC were independent adverse predictors of OS (P = .0015). Additionally, the 2 IHC-defined subtypes were significantly associated with distinct morphological features (P < .001), and there was a significant enrichment of an activated CD8+ cytotoxic phenotype in the PTCL-TBX21 subtype (P = .03). The IHC algorithm will aid in identifying the 2 subtypes in clinical practice, which will aid the future clinical management of patients and facilitate risk stratification in clinical trials.
引用
- Amador C, Greiner TC, Heavican TB, et al. Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. Blood. 2019. PMID: 31562134. doi:10.1182/blood.2019000779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。